This site is intended for US healthcare professionals.
To report an adverse reaction or product complaint, call 1-888-BLUPRNT, option 2, or visit or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Investigator-sponsored trials

Investigator-Sponsored Trials (IST) are clinical or non-clinical research studies or trials initiated, sponsored, and managed by researchers who are not directly affiliated with a manufacturer.

Blueprint Medicines is committed to supporting ISTs that contribute to the scientific and medical understanding of our products and relevant disease areas in order to enhance the practice of medicine and, ultimately, improve patient care. We may provide monetary, in-kind, or other support in response to unsolicited IST requests. All IST requests will be critically reviewed, and a decision will be made based on scientific merit, feasibility, and our current research objectives and available resources. Proposals that directly compete with our current and/or future studies will not be considered.

Areas of research interest

Blueprint Medicines will consider IST proposals in the following areas of interest:

AVAPRITINIB

  • Systemic mastocytosis and other hematologic malignancies
  • Non-malignant diseases, including mast cell disorders

PRALSETINIB

  • Use in RET-altered tumors
  • Use in other solid tumors with RET pathway activation
SYSTEMIC MASTOCYTOSIS
Request for Proposal

Find out more

How to submit an IST request

Brief requests for IST support (IST Concept) must be submitted via the Blueprint Medicines funding portal. The IST Concept will be reviewed by the Blueprint Medicines Scientific Review Committee (SRC). If the SRC approves the IST Concept according to the criteria described above, the investigator will be invited to submit a more detailed proposal containing the following, at a minimum:

  • A comprehensive description of the proposed IST study, including the nature and scope of the support requested
  • A curriculum vitae (CV) or resume that documents previous clinical research experience of the proposed investigator(s) and other key research staff
  • Evidence of good medical standing, including no restrictions by a regulatory authority (debarment) to undertake clinical research, if applicable
  • Detailed project budget, including itemization of costs and services
  • Proposed IST timelines and milestones, including a description of anticipated post-IST activities and publications
  • Any additional relevant supporting documentation required by the SRC

Blueprint Medicines is not obligated to accept any IST requests. We require a fully executed contract prior to initiating support.

Blueprint Medicines is committed to transparency in its interactions with healthcare professionals and healthcare organizations/institutions consistent with applicable laws and/or codes of practice applicable to the pharmaceutical industry.

Last updated on March 1, 2022.

Contact Blueprint Medicines

Submit a medical inquiry Request information about our products.

Contact our medical information teammedinfo@blueprintmedicines.com or 1-888-258-7768 (Option 2)

Blueprint Medicines is a pharmaceutical company focusing on the research, development, and commercialization of products in oncology, hematology, and rare diseases. This website is for US healthcare professionals for educational purposes only. Scientific information and data may include investigational use(s) of compounds for which efficacy and safety have not been established. Blueprint Medicines does not promote or endorse the use of its products in a manner not consistent with the approved label.